Experimental cancer combo tested in tiny, terminated trial
NCT ID NCT05571969
First seen Jun 11, 2026 · Last updated Jun 20, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called 2X-121, alone and combined with another drug called dovitinib, in 14 people with advanced solid tumors. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited and no conclusions about effectiveness can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Carolina BioOncology
Huntersville, North Carolina, 28078, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
2X-121 (a PARP inhibitor) and dovitinib (a targeted cancer drug)
What this could lead to
If successful, this could point toward a new combination treatment for advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This was a very early (Phase 1) safety study that was terminated early with only 14 participants. The drugs may cause significant side effects, and it is unknown if they will shrink tumors or improve survival.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.